[Therapy of anal cancer].
The primary non-invasive treatment of anal-carcinoma by radiochemotherapy (RCT) is generally accepted although prospective randomised trials have not been finished yet. Finally the complex interaction of the radiotherapy and the commonly used cytotoxic agents 5-FU and Mitomycin-C are unknown, besides the radiosensitization. In the radiotherapy quality assurance is warranted in different radiotherapy-techniques and the total and single doses are well established for primary tumor (50-55 Gy) and lymphatic pathways (40-50 Gy) with 1,8 Gy single dose per fraction. According to the slow tumor regression restaging is made three months after completion of RCT. Residual tumor needs abdomino-perineal-resection.
Klinik für Allgemein- und Abdominalchirurgie, Zentralklinikum Augsburg.
H
H
Witzigmann
J
J
Sagasser
F M
FM
Meyer
J
J
Witte
D001003:Anal Canal / Q000528:radiation effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001005:Anus Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D003131:Combined Modality Therapy; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008197:Lymph Node Excision; D015182:Lymphatic Irradiation; D008207:Lymphatic Metastasis; D016685:Mitomycin / Q000008:administration & dosage; D009367:Neoplasm Staging; D011832:Radiation Injuries / Q000209:etiology; D011879:Radiotherapy Dosage; D012004:Rectal Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D012007:Rectum / Q000528:radiation effects; D013524:Surgical Flaps
D016685:Mitomycin; D005472:Fluorouracil
Therapie des Analcarcinoms.